Clinical Trials Browser

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Breast

Triple Negative Breast Neoplasms

NCT04417062 2026-02-25

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Phase 2 Active not recruiting

63 enrolled

Sarcoma

Osteosarcoma

NCT04065269 2026-02-20

ATARI

Phase 2 Active not recruiting

174 enrolled

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

96 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04699838 2026-01-02

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Phase 2 Recruiting

30 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer

NCT06680050 2025-12-18

AUSTRAL

Phase 2 Recruiting

21 enrolled

Thoracic

Non Small Cell Lung Cancer NSCLC

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04564027 2025-08-29

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Phase 2 Completed

54 enrolled 16 charts

Hereditary Sensory and Autonomic Neuropathies

NCT05582538 2025-08-24

ATRiBRAVE

Phase 2 Recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

Phase 2 Recruiting

119 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05061134 2025-07-31

MONETTE

Phase 2 Active not recruiting

194 enrolled 21 charts

Dermatologic

Melanoma

Clinical Trials

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

CAPRI

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

LOTOS

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Olaparib With Ceralasertib in Recurrent Osteosarcoma

ATARI

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

AUSTRAL

HUDSON

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

ATRiBRAVE

PHOENIX

MONETTE